Bioserve India granted NABL accreditation in the field of Genomics Testing Clinical Capabilities • 9 August 2022

Hyderabad, India - 9 August 2022:We are pleased to announce that Bioserve Biotechnologies India Pvt Ltd, a subsidiary of REPROCELL Inc, has received NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation for Medical Testing in the field of Genomics Testing Services. The accreditation is in accordance with ISO 15189: 2012 "Medical laboratories - Requirements for quality and competence".

The letter for NABL accreditation has been issued to Bioserve Biotechnologies India Pvt Ltd. on 3rd August 2022. This laboratory accreditation ensures that the data released from this accredited lab inspires trust and confidence in its accuracy and precision.

Bioserve is a dynamic biotechnology organization primarily centered on clinical diagnostics solutions. One of the areas of scope under this accreditation is BRCA 1 & 2 gene sequencing test, which is a key service provided by the company in the area of precision oncology. Bioserve is also known as one of the leading oligosynthesis service providers and has a strong foothold in molecular genomic services.

Rama Modali, CEO of Bioserve Biotechnologies, mentioned that "We are pleased to receive the NABL accreditation for our clinical diagnostic services, which ensures the trusted consistency and confidence in our laboratory management and data quality. It is our topmost value in our service."

NABL accreditation
NABL stands for National Accreditation Board for Testing and Calibration Laboratories. This accreditation board is a part of the Quality Council of India. The main aim of this institution is to provide an assessment of the quality standards for organizations that provide laboratory/medical tests in the area of such as medical research, clinical diagnostics, bioengineering, and pharmacy.